The Supreme Court ruled unanimously on Thursday, June 14, to return to the 2nd Circuit Court of Appeals a case brought in 2005 by Texas-based Animal Science Products Inc and New Jersey-based The Ranis Co Inc who accused Hebei Welcome Pharmaceutical and North China Pharmaceutical Group and other Chinese vitamin C makers of antitrust violations. A jury trial in 2013 resulted in the plaintiffs being awarded US$147 million in damages, but its ruling was overturrned by the 2nd Circuit on grounds that the court should have deferred to Chinese law as interpreted by that country’s government.
Featured News
Carey Bolsters Competition Law Team With New Senior Counsel
Mar 15, 2026 by
CPI
TikTok US Sale Could Deliver $10 Billion Windfall to the United States
Mar 15, 2026 by
CPI
States Press Ahead With Live Nation Antitrust Trial After Federal Settlement
Mar 15, 2026 by
CPI
US Pulls Back Draft Regulation Targeting Global AI Chip Shipments
Mar 15, 2026 by
CPI
Selecta and Bondholders Ask US Court to Dismiss Antitrust Lawsuit Over Creditor Pact
Mar 15, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Behavioral Economics
Feb 22, 2026 by
CPI
Behavioral Antitrust in 2026
Feb 22, 2026 by
Maurice Stucke
Behavioral Economics in Competition Policy: Going Beyond Inertia and Framing Effects
Feb 22, 2026 by
Annemieke Tuinstra & Richard May
Agreeing to Disagree in Antitrust
Feb 22, 2026 by
Jorge Padilla
Recognizing What’s Around the Corner: Merger Control, Capabilities, and the New Nature of Potential Competition
Feb 22, 2026 by
Magdalena Kuyterink & David J. Teece